Antibiotic susceptibility of canine Bordetella bronchiseptica isolates.
The antimicrobial sensitivities of 78 recent (1995-1998) canine isolates of Bordetella bronchiseptica from 13 separate sources were determined. Minimum inhibitory concentrations were assessed using the E-test method or by agar dilution. All 78 isolates were sensitive to tetracycline, doxycycline, enrofloxacin, and amoxycillin/clavulanic acid; the majority were sensitive to ampicillin (63/78; 81%), trimethoprim (57/78; 73%), and sulphadiazine (63/78; 81%). Plasmids were detected in 14 out of the 24 isolates tested. There was no correlation between the presence of plasmids and antibiotic resistance, but there was some correlation between the presence of plasmids and the origin of the isolates. Three sizes of plasmid were found: 20, 14, and 5.5 kb. Eight of the isolates contained all three plasmids, the remainder one or two, Thirteen isolates demonstrated beta-haemolysis, of which six produced a soluble haemolysin. Except for one isolate, haemolysin production correlated with plasmid carriage. Pulsed-field gel electrophoresis showed that all except one isolate could be grouped in the same genotype. Within this genotype isolates could be divided into three subtypes, generally corresponding to their place of origin.
Speakman
A J
AJ
Department of Veterinary Pathology, University of Liverpool, UK.
Dawson
S
S
Corkill
J E
JE
Binns
S H
SH
Hart
C A
CA
Gaskell
R M
RM
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology / Q000627:therapeutic use; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology / Q000627:therapeutic use; D001885:Bordetella Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D016950:Bordetella bronchiseptica / Q000737:chemistry / Q000145:classification / Q000187:drug effects*; D004269:DNA, Bacterial / Q000737:chemistry; D004283:Dog Diseases / Q000188:drug therapy / Q000382:microbiology*; D004285:Dogs; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use; D016521:Electrophoresis, Gel, Pulsed-Field / Q000662:veterinary; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D011815:R Factors / Q000302:isolation & purification; D013411:Sulfadiazine / Q000494:pharmacology / Q000627:therapeutic use; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D010406:Penicillins; D015363:Quinolones; D013411:Sulfadiazine; D000077422:Enrofloxacin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000667:Ampicillin; D014295:Trimethoprim; D013752:Tetracycline; D004318:Doxycycline